Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice Recommendation for Adults with Chronic Plaque Psoriasis

Approved by NICE for patients with severe plaque psoriasis as defined by PASI and DLQI greater than or equal to 10 Novel oral treatment that does not require regular laboratory monitoring Recognised by NICE as an oral alternative to existing injectable biological therapies